A Belgian start-up company with technology for targeting misfolded proteins closed a €18.3 million Series A financing round in early June. Amyl Therapeutics BV has a preclinical portfolio of therapeutics intended to treat amyloidosis, a group of diseases associated with the build-up of the abnormal amyloid protein in organs of the body. The targets of the company’s research are progressive peripheral and neurodegenerative rare diseases. The company did not identify the diseases by name.
